

FEATURES COHORT I	Invasive carcinoma (n=116)
<i>Age (years)</i>	
≤ 50	46 (39.7%)
> 50	69 (59.4%)
Unknown	1 (0.9%)
<i>Histological grade</i>	
I	12 (10.3%)
II	35 (30.2%)
III	68 (58.6%)
Unknown	1 (0.9)
<i>In situ component</i>	
present	78 (67.3%)
absent	34 (29.3%)
NA	4 (3.4%)
<i>Histological subtype</i>	
Ductal carcinoma	116 (100%)
Others	0 (0%)
<i>Tumour size (cm)</i>	
Tx	1 (0.9%)
T1 (<2)	81 (69.8%)
T2 (2 - 5)	33 (28.4%)
T3 (>5)	1 (0.9%)
<i>N stage</i>	
NX	1 (0.9)
N0	64 (55.2%)
N1	39 (33.6%)
N2	8 (6.9%)
N3	4 (3.4%)
<i>ER</i>	
Positive	38 (32.7%)
Negative	78 (67.3%)

Unknown	0 (0%)
<i>PR</i>	
Positive	35 (30.2%)
Negative	81 (69.8%)
Unknown	0 (0%)
<i>HER2</i>	
Positive	19 (16.4%)
Negative	97 (83.6%)
Unknown	0 (0%)
<i>Ki67</i>	
Positive (≥20%)	95 (81.9%)
Negative (<20%)	19 (16.4%)
Unknown	2 (1.7%)
<i>Molecular subtype</i>	
TNBC	61 (52.6%)
HER2	18 (15.5%)
Luminal A	20 (17.2%)
Luminal B	16 (13.8%)
Luminal B / HER2	1 (0.9%)

FEATURES COHORT II	Invasive carcinoma (n=42)	In situ Carcinoma (n=16)
<i>Age (years)</i>		
≤ 50	14 (33.4%)	6 (37.5%)
> 50	28 (66.6%)	10 (62.5%)
<i>Histological grade (invasive tumors)</i>		
I	12 (28.6%)	x
II	18 (42.8%)	x
III	12 (28.6%)	x
<i>In situ component</i>		
present	34 (81%)	x
absent	8 (19%)	x
<i>Nuclear grade (DCIS)</i>		
High	x	15 (94%)
Non high	x	1 (6%)
<i>Histological subtype</i>		
Ductal carcinoma	38 (90.5%)	x
Others	4 (9.5%)	x
<i>Architectural pattern (DCIS)</i>		
Solid	x	10 (62.5%)
Cribriform	x	4 (25,0%)
Papillary	x	1 (6.25%)
Other	x	1 (6.25%)
<i>Tumour size (cm)</i>		
Tis	x	16 (100)
T1 (<2)	22 (52.4%)	x
T2 (2 - 5)	16 (38.1%)	x
T3 (>5)	1 (2.4%)	x
Unknown	3 (7.1%)	x
<i>N stage</i>		
NO	33 (78,6%)	x

N1	6 (14.3%)	x
N2	2 (4.7%)	x
N3	1 (2,4%)	x
<i>ER</i>		
Positive	32 (76.2%)	13 (81.2%)
Negative	9 (21.4%)	2 (12.5%)
Unknown	1 (2.4%)	1 (6.3%)
<i>PR</i>		
Positive	28 (66.7%)	12 (75.0%)
Negative	13 (30.9%)	3 (18.7%)
Unknown	1 (2.4%)	1 (6.3%)
<i>HER2</i>		
Positive	5 (11.9%)	15 (40,6%)
Negative	36 (85.7%)	22 (59,4%)
Unknown	1 (2.4%)	
<i>Ki67</i>		
Positive (≥20%)	24 (57.1%)	x
Negative (<20%)	17 (40.5%)	x
Unknown	1 (2.4%)	
<i>Molecular subtype</i>		
TNBC	6 (14,3%)	
HER2	3 (7.2%)	
Luminal A	16 (38,1%)	
Luminal B	15 (35,7%)	
Luminal B / HER2	2 (4.7%)	

FEATURES COHORT III	Invasive carcinoma (n=57)
<i>Age (years)</i>	
≤ 50	21 (36.8%)
> 50	5 (61.4%)
Unknown	1 (1.8%)
<i>Histological grade (invasive tumors)</i>	
I	8 (14.0%)
II	23 (40.4%)
III	20 (35.1%)
Unknown	6 (10.5%)
<i>Histological subtype</i>	
Ductal carcinoma	47 (82.5%)
Others	8 (14.0%)
Unknown	2 (3.5%)
<i>Tumour size (cm)</i>	
T1 (<2)	29 (50.9%)
T2 (2 - 5)	12 (21.0%)
T3 (>5)	4 (7.0%)
T4	4 (7.0%)
Unknown	8 (14.1%)
<i>N stage</i>	
N0	21 (36.8%)
N1	18 (31.6%)
N2	6 (10.5%)
N3	5 (8.8%)
Unknown	7 (12.3%)
<i>ER</i>	
Positive	32 (56.1%)
Negative	23 (40.3%)
Unknown	2 (3.6%)

PR

Positive	24 (42.1%)
Negative	31 (54.3%)
Unknown	2 (3.6%)

HER2

Positive	15 (26.3%)
Negative	39 (68.4%)
Unknown	3 (5.3%)

Ki67

Positive ($\geq 20\%$)	39 (68.4%)
Negative ($< 20\%$)	15 (26.3%)
Unknown	3 (5.3%)

Molecular subtype

TNBC	16 (28,1%)
HER2	8 (14.0%)
Luminal A	12 (21.0%)
Luminal B	11 (19.3%)
Luminal B / HER2	7 (12.3%)
Unknown	3 (5.3%)